M. Carlsson

发表

Real-World Patterns of Care for the Overactive Bladder Syndrome in the United States.

K. Zou, J. Anger, H. Goldman, 2016, Urology.

A comparison of nonparametric and parametric methods to adjust for baseline measures.

K. Zou, M. Carlsson, Ching-Ray Yu, 2014, Contemporary clinical trials.

Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head‐to‐head, placebo‐controlled trial

S. Kaplan, M. Carlsson, J. Foote, 2011, BJU international.

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head‐to‐head placebo‐controlled trial

S. Herschorn, M. Brodsky, M. Carlsson, 2010, BJU international.

Extended‐release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score

C. Roehrborn, S. Kaplan, M. Chancellor, 2008, BJU international.

A feasibility study comparing pharmacist and physician recommendations for sildenafil treatment.

T. Symonds, A. Carr, J. Dean, 2011, The journal of sexual medicine.

Repurposing historical control clinical trial data to provide safety context.

M. Cantor, M. Carlsson, J. Desai, 2016, Drug discovery today.

Long‐term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms

J. Heesakkers, P. V. van Kerrebroeck, M. Carlsson, 2010, International journal of clinical practice.

A Comparison of Methods for Adjusting for the Baseline Measure

M. Carlsson, Ching-Ray Yu, Franklin W. Sun, 2011 .

Treatment response to sildenafil in men with erectile dysfunction relative to concomitant comorbidities and age

I. Goldstein, V. Stecher, M. Carlsson, 2017, International journal of clinical practice.

Clinically meaningful improvement on the Self-Esteem And Relationship questionnaire in men with erectile dysfunction

J. Cappelleri, M. O'Leary, V. Stecher, 2007, Quality of Life Research.

A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older

M. Oelke, S. Herschorn, F. Haab, 2017, Age and ageing.

Predictors of Erectile Function Normalization in Men With Erectile Dysfunction Treated With Placebo.

V. Stecher, J. Mulhall, M. Carlsson, 2018, The journal of sexual medicine.

Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health‐related quality of life in patients with overactive bladder treated with tolterodine

K. Coyne, M. Brodsky, V. Elinoff, 2008, International journal of clinical practice.

Bmc Medical Research Methodology Open Access a Meta-analysis of the Placebo Response in Antimuscarinic Drug Trials for Overactive Bladder

P. Glue, M. Carlsson, B. Malhotra, 2022 .

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

C. Roehrborn, S. Kaplan, T. Bavendam, 2006, JAMA.

Tolterodine extended release is well tolerated in older subjects

S. Kraus, T. Griebling, M. Carlsson, 2009, International journal of clinical practice.

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER

S. Kaplan, L. Cardozo, T. Crook, 2014, International journal of clinical practice.

The clinical efficacy of tolterodine extended‐release is maintained for 24 h in patients with overactive bladder

R. Dmochowski, K. Kreder, S. Macdiarmid, 2007, BJU international.

Tolterodine extended release improves patient‐reported outcomes in overactive bladder: results from the IMPACT trial

R. Roberts, V. Elinoff, T. Bavendam, 2006, International journal of clinical practice.

Symptom‐specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial

V. Elinoff, T. Bavendam, M. Carlsson, 2006, International journal of clinical practice.

Long-Term Safety, Tolerability and Efficacy of Fesoterodine in Subjects with Overactive Bladder Symptoms Stratified by Age

S. Kraus, J. Heesakkers, M. Carlsson, 2012, Drugs & Aging.

Sustained improvement in patient‐reported outcomes during long‐term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open‐label extension studies

R. Dmochowski, C. Kelleher, Z. Kopp, 2012, BJU international.

Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms

C. Kelleher, T. Bavendam, M. Carlsson, 2011, Current medical research and opinion.

Original article Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms

C. Kelleher, T. Bavendam, M. Carlsson, 2011 .

Onset of efficacy of tolterodine extended release in patients with overactive bladder*

S. Kraus, M. Carlsson, Z. Guan, 2007, Current medical research and opinion.

Optimal thresholds by maximizing or minimizing various metrics via ROC-type analysis.

Kelly H. Zou, Ching-Ray Yu, Martin O. Carlsson, 2013, Academic radiology.

Detecting data fabrication in clinical trials from cluster analysis perspective

Martin Carlsson, Xiaoru Wu, M. Carlsson, 2011, Pharmaceutical statistics.

Clinically meaningful improvement on the quality of erection questionnaire in men with erectile dysfunction

T. Symonds, V. Stecher, M. Carlsson, 2010, International Journal of Impotence Research.

Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients

M. Korbonits, A. V. van Beek, P. Touraine, 2022, The Journal of clinical endocrinology and metabolism.

Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil.

J. Cappelleri, S. McKenna, M. Carlsson, 2009, Chest.

Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.

S. Kaplan, K. Kreder, T. Bavendam, 2008, The Journal of urology.

Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders

J. Weiss, M. Carlsson, E. Mangan, 2017, The Journal of urology.

Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States

K. Zou, J. Anger, H. Goldman, 2018, Neurourology and urodynamics.

Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder

J. Corcos, M. Carlsson, J. Angulo, 2011, Current medical research and opinion.

Generalized Estimation of the BLUP in Mixed-Effects Models: A Comparison with ML and REML

Kelly H. Zou, Samaradasa Weerahandi, Ching-Ray Yu, 2014, Commun. Stat. Simul. Comput..

Efficacy and Safety of Sildenafil in Men With Sexual Dysfunction and Spinal Cord Injury.

V. Stecher, D. Ohl, M. Carlsson, 2017, Sexual medicine reviews.

Comparative Effectiveness Research Using Meta-Analysis to Evaluate and Summarize Diagnostic Accuracy

K. Zou, M. Carlsson, Ching-Ray Yu, 2015 .

Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort

M. Maghnie, Raoul Rooman, L. Ibáñez, 2022, The Journal of clinical endocrinology and metabolism.

Predictors of Erectile Function Normalization in Men With Erectile Dysfunction Treated With Placebo.

V. Stecher, J. Mulhall, M. Carlsson, 2018, The journal of sexual medicine.

Beta‐mapping and beta‐regression for changes of ordinal‐rating measurements on Likert scales: A comparison of the change scores among multiple treatment groups

K. Zou, M. Carlsson, S. Quinn, 2010, Statistics in medicine.

C. Roehrborn, M. Chancellor, T. Bavendam, 2008, BJU international.

Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?

M. Oelke, H. Goldman, D. Russell, 2019, International Urogynecology Journal.

What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine

M. Oelke, S. Herschorn, A. Wagg, 2021, Neurourology and urodynamics.